We built Pythia-1, a frontier generative model for therapeutic discovery, to expand the reach of antibody therapeutics to hard-to-drug targets.
In our latest study, we used it to design full-length human antibodies that activate or inhibit GPCRs in cells. To our knowledge, a first for de novo design.
With just one design round and minimal screening, we identified multiple antagonists with single-digit nM inhibitory potency and an agonist with potency comparable to the receptor's natural ligand.
Designed antibodies also demonstrated favorable developability profiles.
Read the preprint: biorxiv.org/content/10.648…
We're releasing the sequences: pythialabs.com
In our latest study, we used it to design full-length human antibodies that activate or inhibit GPCRs in cells. To our knowledge, a first for de novo design.
With just one design round and minimal screening, we identified multiple antagonists with single-digit nM inhibitory potency and an agonist with potency comparable to the receptor's natural ligand.
Designed antibodies also demonstrated favorable developability profiles.
Read the preprint: biorxiv.org/content/10.648…
We're releasing the sequences: pythialabs.com
0:30